Edgar L Milford

US Patent:

7863418, Jan 4, 2011

Filed:

May 10, 2005

Appl. No.:

11/126866

Inventors:

Nalan Utku - Berlin, DE
Steven R. Gullans - Natick MA, US
Edgar L. Milford - Dover MA, US

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA

International Classification:

C07K 14/705
A61K 38/17

US Classification:

530350, 514 12

Abstract:

Described are a T cell immune response cDNA 7 (TIRC7) encoding a T-cell transmembrane protein, peptides and polypeptides derived therefrom and antibodies recognizing such (poly)peptides. Peptides, polypeptides and antibodies capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Vectors comprising polynucelotides encoding such polypeptides and peptides, host cells transformed therewith, and their use in the production of such, peptides or polypeptides are also described.

US Patent:

7931901, Apr 26, 2011

Filed:

Aug 25, 2006

Appl. No.:

11/510868

Inventors:

Nalan Utku - Berlin, DE
Steven R. Gullans - Natick MA, US
Edgar L. Milford - Dover MA, US

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA

International Classification:

A61K 39/395

US Classification:

4241441, 514825, 4241541

Abstract:

Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described. Also, the use of said polynucleotide, vector, protein, peptide, polypeptide, or antibody for the preparation of pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided.

US Patent:

20030124614, Jul 3, 2003

Filed:

May 13, 2002

Appl. No.:

10/145012

Inventors:

Nalan Utku - Berlin, DE
Steven Gullans - Natick MA, US
Edgar Milford - Dover MA, US

Assignee:

Brighams and Womens Hospital Inc.

International Classification:

G01N033/53

US Classification:

435/007100

Abstract:

Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described. Also, the use of said polynucleotide, vector, protein, peptide, polypeptide, or antibody for the preparation of pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided. Furthermore, methods for modulating (antigen-specific) T cell unresponsiveness inducing maintaining or reversing T cell unresponsiveness by inhibiting or stimulating an (unresponsive) T cell through the novel TIRC7 membrane protein are encompassed herein.

US Patent:

20050271659, Dec 8, 2005

Filed:

May 10, 2005

Appl. No.:

11/126841

Inventors:

Nalan Utku - Berlin, DE
Steven Gullans - Natick MA, US
Edgar Milford - Dover MA, US

International Classification:

A61K039/395
A61K038/17
C07K014/74
C07K016/28

US Classification:

424144100, 536023500, 530350000, 435069100, 435320100, 435325000, 530388220, 514012000

Abstract:

Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described. Also, the use of said polynucleotide, vector, protein, peptide, polypeptide, or antibody for the preparation of pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided. Furthermore, methods for modulating (antigen-specific) T cell unresponsiveness inducing maintaining or reversing T cell unresponsiveness by inhibiting or stimulating an (unresponsive) T cell through the novel TIRC7 membrane protein are encompassed herein.

US Patent:

20070212714, Sep 13, 2007

Filed:

Jan 16, 2007

Appl. No.:

11/654267

Inventors:

Nalan Utku - Berlin, DE
Edgar Milford - Dover MA, US

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

Described are generally immune response cDNA TZap7/A, TZap7/B and TZap7 polynucleotides encoding novel proteins involved in modulation of immune responses and antibodies recognizing said proteins. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore-described polynucleotides, vectors, proteins, or antibodies. Furthermore, methods and uses for modulating immune responses through the novel TZap protein as well as pharmaceutical compositions comprising agents which act on the TZap protein or its ligand are described. Also, the use of said polynucleotides, vectors, proteins or antibodies for the preparation of diagnostic and pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided.

US Patent:

45172897, May 14, 1985

Filed:

Aug 18, 1982

Appl. No.:

6/409183

Inventors:

Edgar L. Milford - Dover MA
Charles B. Carpenter - Weston MA
Jean M. Paradysz - Brighton MA

Assignee:

Brigham and Women's Hospital - Boston MA

International Classification:

G01N 3354
C12N 500
C12N 1500
C12R 191
A61K 39395

US Classification:

435 7

Abstract:

Immortal, antibody-producing, hybridomally-produced clones which produce antibodies that react specifically with human HLA antigens and which are produced from rat lymphocyte cells sensitized against cells from a rat strain having different histocompatibility antigens are disclosed along with methods of producing the clones and antibodies and methods of using the antibodies in tissue crossing tests.